MRI-guided region-of-interest delineation is comparable to manual delineation in dopamine transporter SPECT quantification in patients: A reproducibility study

Journal of Nuclear Medicine Technology

Volumn 38, Issue 2, 2010, Pages 61-68

  Ziebell, Morten ^a   Pinborg, Lars H ^a   Thomsen, Gerda ^a   de Nijs, Robin ^a   Svarer, Claus ^a   Wagner, Aase ^a   Knudsen, Gitte M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

123I PE2I; Dopamine transporters; Reproducibility; ROI delineation; SPECT

Indexed keywords

DOPAMINE TRANSPORTER; IODINE 123; N (3 IODOPROP ENYL) 2 BETA CARBOXYMETHOXY 3 BETA (4' METHYLPHENYL) NORTROPANE; NORTROPANE DERIVATIVE; RADIOLIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BINDING KINETICS; CLINICAL ARTICLE; CORPUS STRIATUM; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSONISM; REPRODUCIBILITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; COMPARATIVE STUDY; IMAGE PROCESSING; METABOLISM; METHODOLOGY; MIDDLE AGED; OBSERVER VARIATION; STATISTICS;

AGED; AGED, 80 AND OVER; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OBSERVER VARIATION; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 77956217290     PISSN: 00914916     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnmt.109.072801     Document Type: Article

References (31)

1. Bao SY, Wu JC, Luo WF, Fang P, Liu ZL, Tang J. Imaging of dopamine transporters with technetium-99m TRODAT-1 and single photon emission computed tomography. J Neuroimaging. 2000;10:200-203.
2. 123I] β-CIT and SPECT: correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl. 1997;50:9-24.
3. 123I-PE2I SPECT. Neuroimage. 2003;19:810-816.
4. Emond P, Guilloteau D, Chalon S. PE2I: a radiopharmaceutical for in vivo exploration of the dopamine transporter. CNS Neurosci Ther. 2008;14:47-64.
5. Marshall V, Grosset D. Role of dopamine transporter imaging in routine clinical practice. Mov Disord. 2003;18:1415-1423.
6. Scherfler C, Schwarz J, Antonini A, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord. 2007;22:1229-1238.
7. Morrish PK. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? Mov Disord. 2003;18(suppl 7):S63-S70.
8. Poewe W, Scherfler C. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov Disord. 2003;18(suppl 7):S16-S21.
9. Knudsen GM, Karlsborg M, Thomsen G, et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging. 2004;31:1631-1638.
10. Innis RB, Seibyl JP, Scanley BE, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA. 1993;90:11965-11969.
11. Marek K, Jennings D, Seibyl J. Do dopamine agonists or levodopa modify Parkinson's disease progression? Eur J Neurol. 2002;9(suppl 3):15-22.
12. Zaidi H, El Fakhri G. Is absolute quantification of dopaminergic neurotransmission studies with 123I SPECT ready for clinical use? Eur J Nucl Med Mol Imaging. 2008;35:1330-1333.
13. 11C]PE2I and positron emission tomography. J Cereb Blood Flow Metab. 2009;29:1332-1345.
14. Koch W, Radau PE, Hamann C, Tatsch K. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. J Nucl Med. 2005;46:1109-1118.
15. 123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. 2006;33:1491-1499.
16. Seibyl JP, Laruelle M, van Dyck CH, et al. Reproducibility of iodine-123-β-CIT SPECT brain measurement of dopamine transporters. J Nucl Med. 1996;37:222-228.
17. 123I]PE2I binding to dopamine transporters with SPECT. Eur J Nucl Med Mol Imaging. 2007;34:101-109.
18. Booij J, Habraken JB, Bergmans P, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. J Nucl Med. 1998;39:1879-1884.
19. 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. J Nucl Med. 2004;45:207-213.
20. Seibyl JP, Marek K, Sheff K, et al. Test/retest reproducibility of iodine-123-βCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. J Nucl Med. 1997;38:1453-1459.
21. 123I-FPCIT SPECT in normal control and Parkinson's disease patients. Ann Nucl Med. 2004;18:609-616.
22. 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. J Nucl Med. 2005;46:1119-1127.
23. 123I imaging. Phys Med Biol. 2006;51:N307-N311.
24. de Nijs R, Svarer C, Holm S. Correction for high energy photons and scatter for dynamic SPECT studies with I-123 [abstract]. Eur J Nucl Med Mol Imaging. 2004;31(suppl 2):402.
25. Kretschmann H-J, Weinrich W. Neuroanatomy and Cranial Computed Tomography. Stuttgart, Germany: Thieme; 1986.
26. Svarer C, Madsen K, Hasselbalch SG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage. 2005;24:969-979.
27. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533-1539.
28. Ichise M, Ballinger JR, Vines D, Tsai S, Kung HF. Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjects. J Nucl Med. 1997;38:31-37.
29. van Dyck CH, Seibyl JP, Malison RT, et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry. 2002;10:36-43.
30. 18F]-altanserin PET study. Eur J Nucl Med Mol Imaging. 2008;35:1-4.
31. Pirker W, Djamshidian S, Asenbaum S, et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: a longitudinal β-CIT SPECT study. Mov Disord. 2002;17:45-53.